1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Morepen Laboratories Limited

Morepen Laboratories Limited

MOREPENLAB.BO
Morepen Laboratories LimitedIN flagBombay Stock Exchange
60.78
INR
+1.79
- -
33.25BMarket Cap

Total Valuation

Morepen Laboratories Limited carries a market capitalization of 33.25B, placing it among publicly traded companies globally. Its enterprise value stands at 19.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap33.25B
Enterprise Value19.56B

Share Statistics

Morepen Laboratories Limited currently has 547.95M shares outstanding.

Shares Outstanding547.95M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Morepen Laboratories Limited trades at a trailing price-to-earnings ratio of 19.55. The price-to-sales ratio is 1.03, and the price-to-book ratio stands at 16.92.

PE Ratio19.55
PS Ratio1.03
PB Ratio16.92
P/TBV Ratio1.64
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Morepen Laboratories Limited trades at an EV/EBITDA multiple of 21.92 and an EV/FCF ratio of 149.38. The EV/Sales ratio of 1.08 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 21.92 provides insight into valuation relative to core operating earnings.

EV / Sales1.08
EV / EBITDA21.92
EV / EBIT21.92
EV / FCF149.38

Financial Position

Morepen Laboratories Limited maintains a current ratio of 2.37, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.67, indicating elevated leverage, while an interest coverage ratio of 5.43 demonstrates adequate ability to service its debt obligations.

Current Ratio2.37
Quick Ratio0.22
Debt / Equity16.67
Debt / EBITDA2.33
Interest Coverage5.43

Financial Efficiency

Morepen Laboratories Limited posts a return on equity of 30.44 and a return on invested capital of 5.18.

Return on Equity (ROE)30.44
Return on Assets (ROA)5.11
Return on Invested Capital (ROIC)5.18
Return on Capital Employed (ROCE)22.16
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.93

Taxes

Over the trailing twelve months, Morepen Laboratories Limited has paid 242.74M in income taxes, reflecting an effective tax rate of 20.24.

Income Tax242.74M
Effective Tax Rate20.24

Stock Price Statistics

Morepen Laboratories Limited's stock has declined approximately -4.58399% over the past 52 weeks. The 50-day moving average sits at 39.86, while the 200-day moving average is 51.59.

Beta (5Y)N/A
52-Week Price Change-4.58399%
50-Day Moving Average39.86
200-Day Moving Average51.59
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Morepen Laboratories Limited generated 18.06B in revenue and converted that into 948.77M in net income, yielding earnings per share of 1.74. EBITDA reached 891.94M, while operating income came in at 891.94M.

Revenue18.06B
Gross Profit6.82B
Operating Income891.94M
Pretax Income1.20B
Net Income948.77M
EBITDA891.94M
EBIT891.94M
Earnings Per Share (EPS)1.74

Balance Sheet

Morepen Laboratories Limited holds 1.08B in cash and equivalents against 2.08B in total debt, resulting in a net debt position of 1.64B. Total book value stands at 1.10B, with working capital of 6.73B providing operational flexibility.

Cash & Cash Equivalents1.08B
Total Debt2.08B
Net Debt1.64B
Equity (Book Value)1.10B
Book Value Per Share2.00
Working Capital6.73B

Margins

Morepen Laboratories Limited operates with a gross margin of 37.78, reflecting its pricing power and cost economics. The operating margin of 4.94 and net profit margin of 5.25 provide insight into operational efficiency.

Gross Margin37.78
Operating Margin4.94
Pretax Margin6.64
Profit Margin5.25
EBITDA Margin4.94

Stock Splits

Morepen Laboratories Limited's most recent stock split took place on November 7, 2000 with a 1:5 split ratio.

Last Split Date11/7/2000
Split Ratio1:5

Scores

Morepen Laboratories Limited posts an Altman Z-Score of 3.22, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.22